Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Jul 22 03:57PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-3.13 Insider Own15.86% Shs Outstand30.10M Perf Week7.29%
Market Cap124.30M Forward P/E- EPS next Y-2.30 Insider Trans3.72% Shs Float25.39M Perf Month35.53%
Income-94.30M PEG- EPS next Q-0.83 Inst Own47.45% Short Float3.99% Perf Quarter3.00%
Sales0.00M P/S- EPS this Y8.31% Inst Trans4.25% Short Ratio9.63 Perf Half Y19.77%
Book/sh2.39 P/B1.73 EPS next Y23.44% ROA-85.74% Short Interest1.01M Perf Year38.72%
Cash/sh2.77 P/C1.49 EPS next 5Y- ROE-95.48% 52W Range2.41 - 7.22 Perf YTD-0.48%
Dividend Est.- P/FCF- EPS past 5Y-2.94% ROI-130.89% 52W High-42.96% Beta0.49
Dividend TTM- Quick Ratio6.82 Sales past 5Y0.00% Gross Margin- 52W Low70.60% ATR (14)0.25
Dividend Ex-Date- Current Ratio6.82 EPS Y/Y TTM34.48% Oper. Margin0.00% RSI (14)65.49 Volatility6.46% 6.45%
Employees20 Debt/Eq0.00 Sales Y/Y TTM- Profit Margin- Recom2.50 Target Price10.62
Option/ShortYes / Yes LT Debt/Eq0.00 EPS Q/Q17.16% Payout- Rel Volume0.47 Prev Close4.16
Sales Surprise- EPS Surprise15.29% Sales Q/Q- EarningsMay 08 AMC Avg Volume105.32K Price4.12
SMA2018.38% SMA5024.73% SMA2008.86% Trades Volume48,671 Change-0.96%
Date Action Analyst Rating Change Price Target Change
Jun-05-24Downgrade Goldman Neutral → Sell $3 → $2
Oct-14-22Downgrade Truist Buy → Hold $90 → $10
Oct-14-22Downgrade Guggenheim Buy → Neutral
Oct-14-22Downgrade Goldman Buy → Neutral $81 → $8
Oct-13-22Downgrade Oppenheimer Outperform → Perform $64 → $7
Nov-18-21Initiated Mizuho Buy $50
May-20-21Resumed Goldman Buy $78
Oct-28-20Downgrade Goldman Buy → Neutral $69 → $40
Jul-14-20Initiated Oppenheimer Outperform $75
May-04-20Initiated SunTrust Buy $75
Jun-18-24 08:30AM
Jun-10-24 07:30AM
Jun-03-24 07:30AM
May-28-24 06:10AM
May-11-24 08:41AM
06:20AM Loading…
May-09-24 06:20AM
May-08-24 09:55PM
May-06-24 07:30AM
Mar-20-24 10:27AM
Mar-19-24 08:52PM
07:30AM Loading…
Mar-12-24 07:30AM
Mar-05-24 07:30AM
Feb-01-24 03:02PM
Jan-05-24 05:12PM
Jan-04-24 07:30AM
Dec-29-23 08:47AM
Dec-20-23 02:39PM
Nov-10-23 01:57PM
Nov-08-23 06:47PM
Nov-03-23 07:30AM
Oct-11-23 08:31AM
Oct-09-23 07:30AM
Oct-06-23 07:30AM
08:30AM Loading…
Sep-20-23 08:30AM
Aug-23-23 07:30AM
Aug-08-23 04:01PM
Aug-01-23 07:30AM
Jul-31-23 06:10AM
Jun-08-23 07:30AM
Jun-02-23 07:30AM
May-24-23 07:42AM
May-11-23 04:01PM
May-08-23 07:30AM
Apr-12-23 12:59PM
Mar-27-23 07:12AM
Mar-24-23 09:08AM
Mar-23-23 04:01PM
Mar-17-23 08:30AM
Feb-27-23 09:13AM
Feb-17-23 06:35AM
Jan-12-23 08:00AM
Jan-09-23 08:00AM
Dec-29-22 09:11AM
Dec-15-22 06:08AM
Dec-08-22 08:39AM
Dec-07-22 04:05PM
Nov-10-22 04:05PM
Nov-08-22 04:15PM
Nov-03-22 12:24PM
Oct-20-22 11:28AM
Oct-14-22 12:55PM
Oct-13-22 04:04PM
Sep-20-22 08:30AM
Aug-14-22 10:14AM
Aug-11-22 04:15PM
Aug-09-22 08:30AM
Aug-05-22 08:30AM
Jul-21-22 08:30AM
Jul-04-22 06:51AM
Jun-07-22 08:30AM
Jun-02-22 08:30AM
May-25-22 08:30AM
May-10-22 12:25PM
May-05-22 04:01PM
Apr-29-22 08:30AM
Apr-28-22 09:00AM
Apr-04-22 09:00AM
Mar-23-22 04:05PM
Mar-16-22 08:30AM
Mar-10-22 08:30AM
Mar-09-22 01:24AM
Mar-08-22 04:00PM
Mar-07-22 05:32PM
Mar-05-22 05:30AM
Mar-03-22 02:04PM
Mar-02-22 01:28PM
Feb-27-22 06:24AM
Feb-23-22 11:42AM
Feb-10-22 08:30AM
Jan-12-22 10:00AM
Dec-22-21 09:02AM
Dec-15-21 09:20AM
Dec-14-21 08:30AM
Relmada Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in addressing diseases of the central nervous system. It develops esmethadone, an N-methyl-D-aspartate receptor antagonist for the treatment of CNS diseases, and oral agent for depression and other potential indications. The company was founded by Paolo Manfredi on May 31, 2012 and is headquartered in Coral Gables, FL.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
TRAVERSA SERGIOChief Executive OfficerJan 31 '24Buy4.0027,460109,752244,024Jan 31 06:29 PM
Ence ChuckCA and COJan 31 '24Buy4.0513,67055,42938,970Jan 31 06:28 PM
Shenouda MagedChief Financial OfficerJan 31 '24Buy4.066,87527,94334,903Jan 31 06:28 PM
TRAVERSA SERGIOChief Executive OfficerJan 30 '24Buy3.9040,999159,949216,564Jan 31 06:29 PM
Shenouda MagedChief Financial OfficerJan 30 '24Buy3.8915,00058,32328,028Jan 31 06:28 PM
Ence ChuckCA and COJan 30 '24Buy3.8714,50056,05325,300Jan 31 06:28 PM
TRAVERSA SERGIOChief Executive OfficerJan 29 '24Buy3.7131,541117,036175,565Jan 31 06:29 PM
Shenouda MagedChief Financial OfficerJan 29 '24Buy3.6510,80039,45013,028Jan 31 06:28 PM
Ence ChuckCA and COJan 29 '24Buy3.6510,80039,43810,800Jan 31 06:28 PM